Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses what he envisions for the future treatment landscape of gastric cancer.
Charles S. Fuchs, MD, MPH
Advertisement
Articles by Charles S. Fuchs, MD, MPH
Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses efficacy and safety results for pembrolizumab (Keytruda) monotherapy in patients with previously treated advanced gastric cancer.
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, on the use of aspirin and targeting COX-2 in colorectal cancer.
Charles S. Fuchs, MD, MPH, director, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute, discusses targeting KRAS in colorectal cancer.
Advertisement
Latest Updated Articles
Aspirin and Targeting COX-2 in Colorectal CancerPublished: January 27th 2014 | Updated:
Efficacy and Safety Results for Pembrolizumab in Previously Treated Gastric CancerPublished: June 13th 2017 | Updated:
- The Future Treatment Landscape of Gastric Cancer
Published: September 22nd 2017 | Updated:
Targeting KRAS in Colorectal CancerPublished: November 22nd 2013 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
